Physician profile
Wilfred Lee
NPI 1629118278
$1,635.71
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,091 · 2020: $301 · 2021: $147 · 2022: $68.51 · 2023: $28.43.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $28.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $28.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $219.03 | 2019-2020 | |
| Pfizer INC. | $214.28 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $193.10 | 2019-2020 | |
| Boston Scientific Corporation | $134.22 | 2019 | |
| Intercept Pharmaceuticals, INC. | $124.64 | 2019-2020 | |
| Conmed Corporation | $107.56 | 2021 | |
| Merck Sharp & Dohme LLC | $103.72 | 2019-2020 | |
| Endogastric Solutions, INC | $96.00 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $75.84 | 2019-2022 | |
| Covidien LP | $75.10 | 2020 | |
| Ironwood Pharmaceuticals, INC | $64.96 | 2019-2020 | |
| Janssen Biotech, INC. | $57.48 | 2019-2022 | |
| Portola Pharmaceuticals, LLC | $30.93 | 2019 | |
| Enterra Medical, INC. | $28.43 | 2023 | |
| Qol Medical, LLC | $28.25 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $23.44 | 2022 | |
| Olympus America INC. | $20.69 | 2019 | |
| Redhill Biopharma INC. | $14.53 | 2022 | |
| Apria Healthcare LLC | $11.77 | 2021 | |
| Shire North American Group INC | $11.74 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wilfred Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.